No Data
Shanghai Shyndec Pharmaceutical's Pravastatin Sodium Tablets Passes Chinese Drug Regulator's Consistency Evaluation
Shanghai Shyndec Pharmaceutical (600420.SH): Simvastatin tablets have passed the consistency evaluation for generic drugs.
On March 3, Glonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that the company received the "Notice of Approval for Supplemental Application for Pharmaceutical" issued by the National Medical Products Administration, approving the sodium pravastatin tablets (10mg) to pass the consistency evaluation of generics in quality and efficacy. Sodium pravastatin tablets are competitive inhibitors that can inhibit HMG-CoA reductase, thereby inhibiting the biosynthesis of cholesterol, suitable for patients with primary hypercholesterolemia or those with combined hypertriglyceridemia (Type IIa and IIb), with primary indications being hyperlipidemia that cannot be controlled by dietary restrictions and familial hypercholesterolemia.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
While Individual Investors Own 30% of Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420), Private Companies Are Its Largest Shareholders With 58% Ownership
Shyndec Pharma's Units Get Three Drug Registration Certificates
Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection